ClinicalTrials.gov
public full text
Public Domain
Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma
This study evaluates the clinical safety and tolerability, and the immunological effects of local intradermal injection of tremelimumab in patients with clinical stage I/II melanoma patients undergoing a sentinel node biopsy (SNB). Patients will be treated by local intradermal injections around the excision site of the primary tumor with escalating doses of 2, 5, 10 or 20 mg tremelimumab.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma#848198
- Vaccine Therapy in Treating Patients With Stage IV Melanoma#283111
- Vaccine Therapy in Treating Patients With Stage IV Melanoma#140992
- IXO (Irinotecan, Xeloda, Oxaliplatin) in Rectal Cancer#869118
- RT-01 Monotherapy and in Combination With Nivolumab in Patients With Advanced Solid Tumors#859696
Record · ID 917180
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive